Guardant Health (NASDAQ:GH) Rating Increased to Strong-Buy at Mizuho

Guardant Health (NASDAQ:GH - Get Free Report) was upgraded by analysts at Mizuho to a "strong-buy" rating in a report released on Wednesday,Zacks.com reports.

GH has been the subject of several other research reports. Stifel Nicolaus increased their price target on Guardant Health from $45.00 to $53.00 and gave the company a "buy" rating in a research note on Friday, February 21st. Canaccord Genuity Group increased their target price on shares of Guardant Health from $42.00 to $60.00 and gave the company a "buy" rating in a research report on Monday, February 24th. The Goldman Sachs Group boosted their price target on shares of Guardant Health from $49.00 to $56.00 and gave the stock a "buy" rating in a research report on Friday, February 21st. Stephens reaffirmed an "overweight" rating and issued a $55.00 price objective on shares of Guardant Health in a research note on Wednesday, March 26th. Finally, Morgan Stanley lifted their target price on shares of Guardant Health from $42.00 to $52.00 and gave the stock an "overweight" rating in a research note on Thursday, March 6th. Twenty investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average price target of $49.00.

Guardant Health Price Performance

Shares of NASDAQ GH traded down $0.31 during mid-day trading on Wednesday, hitting $44.85. 2,021,999 shares of the stock traded hands, compared to its average volume of 2,140,585. The company has a market cap of $5.54 billion, a PE ratio of -12.60 and a beta of 1.45. Guardant Health has a twelve month low of $15.81 and a twelve month high of $50.89. The firm has a 50 day simple moving average of $43.53 and a two-hundred day simple moving average of $35.93.

Remove Ads

Guardant Health (NASDAQ:GH - Get Free Report) last announced its quarterly earnings results on Thursday, February 20th. The company reported ($0.90) EPS for the quarter, missing analysts' consensus estimates of ($0.75) by ($0.15). The firm had revenue of $201.81 million for the quarter, compared to analyst estimates of $192.50 million. Guardant Health had a negative net margin of 59.05% and a negative return on equity of 19,157.20%. On average, equities research analysts anticipate that Guardant Health will post -2.9 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Guardant Health

Large investors have recently added to or reduced their stakes in the business. NewEdge Advisors LLC raised its holdings in shares of Guardant Health by 13.5% in the fourth quarter. NewEdge Advisors LLC now owns 1,929 shares of the company's stock valued at $59,000 after purchasing an additional 230 shares during the last quarter. Summit Investment Advisors Inc. increased its stake in Guardant Health by 3.3% in the 4th quarter. Summit Investment Advisors Inc. now owns 12,346 shares of the company's stock valued at $377,000 after buying an additional 391 shares during the last quarter. Arizona State Retirement System lifted its position in shares of Guardant Health by 1.1% during the 4th quarter. Arizona State Retirement System now owns 35,639 shares of the company's stock worth $1,089,000 after buying an additional 403 shares in the last quarter. Jones Financial Companies Lllp boosted its stake in shares of Guardant Health by 43.5% in the 4th quarter. Jones Financial Companies Lllp now owns 2,696 shares of the company's stock worth $82,000 after buying an additional 817 shares during the last quarter. Finally, Fiduciary Alliance LLC grew its holdings in shares of Guardant Health by 7.6% in the fourth quarter. Fiduciary Alliance LLC now owns 11,879 shares of the company's stock valued at $363,000 after acquiring an additional 836 shares in the last quarter. Institutional investors own 92.60% of the company's stock.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.